Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion

比较根治性子宫切除术与同步放化疗治疗无宫旁浸润的IIICr期宫颈癌的肿瘤学疗效和并发症发生率。

阅读:2

Abstract

BACKGROUND: This study aimed to compare oncological outcomes and complication rates between radical hysterectomy (RH) and concurrent chemoradiotherapy (CCRT) in patients with stage IIICr cervical cancer without parametrial invasion, based on differing treatment protocols at two institutions. METHODS: A total of 106 patients with biopsy-confirmed cervical cancer and lymph node metastasis detected on pretreatment imaging, but without evidence of parametrial invasion, were enrolled. Of these, 55 patients underwent RH, while 51 patients received CCRT. Oncological outcomes, complication rates, and recurrence patterns were analyzed and compared between the two groups. RESULTS: At a median follow-up of 62 months (range, 3-220 months), there were no statistically significant differences in disease-free survival or overall survival between the RH and CCRT groups (p = 0.7788 and p = 0.8757, respectively). However, the incidence of overall complications was significantly higher in the RH group compared to the CCRT group (54.5% vs. 19.6%, p < 0.0001). The RH group also demonstrated a significantly greater frequency of major complications (Clavien-Dindo grade III/IV: 23.6% vs. 3.9%, p < 0.0001). Patterns of recurrence differed between the groups: the RH group exhibited a higher rate of distant metastases (56.2% vs. 16.3%), whereas the CCRT group showed a higher incidence of local recurrence (64.3% vs. 25.0%, p = 0.026). CONCLUSION: There were no significant differences in disease-free or overall survival between patients treated with RH and those treated with CCRT. However, RH was associated with a significantly higher rate of complications. Given these findings, CCRT may represent a more favorable treatment option for patients with stage IIICr cervical cancer without parametrial invasion.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。